Sarepta Therapeutics CEO Doug Ingram to retire after tumultuous decade
Key Points:
- Sarepta Therapeutics’ CEO Doug Ingram said Wednesday he would retire after a tumultuous decade in which he turned the biotech into a $15 billion company by pushing three different treatments for Duche